Independent Board Says AstraZeneca Vaccine Announcement Relied on Old Information
Summary from the AllSides News Team
Featured Coverage of this Story
From the Center
New questions about AstraZeneca vaccine could derail its emergency use in USLate Monday evening, a U.S. public health agency expressed concern regarding the newly released clinical trial results from the pharmaceutical company AstraZeneca’s COVID-19 vaccine candidate.
Following the release of promising data showing high levels of efficacy in preventing a COVID-19 infection and severe outcomes, AstraZeneca officials confirmed they would be seeking the U.S. Food and Drug Administration’s (FDA) emergency use authorization.
This could be derailed as a public health oversight committee, the Data and Safety Monitoring Board (DSMB) said the clinical trials could have used outdated information in the trials,...
From the Right
AstraZeneca Cherry-Picked Data, Misrepresented Vaccine’s Efficacy, Independent Medical Board AllegesAn independent panel of medical experts overseeing AstraZeneca’s coronavirus vaccine trial accused the pharmaceutical company of cherry-picking favorable data, The New York Times reported.
The Data and Safety Monitoring Board (DSMB) alleged that AstraZeneca misrepresented the results of its coronavirus vaccine trial when it announced Monday morning that the vaccine had 79% efficacy at preventing symptomatic coronavirus, according to the NYT. The panel wrote a sharply-worded letter to the British pharmaceutical company and U.S. health officials hours after the results were released, triggering the National Institute of Allergy and Infectious...
From the Left
Trial review board raises concerns about AstraZeneca vaccine dataIn an unusual statement released early Tuesday, the National Institute of Allergy and Infectious Diseases said the independent board that reviews data from multiple Covid-19 vaccine candidates has raised concerns about AstraZeneca's announcement of efficacy data from its vaccine trial.
"The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," said the NIAID statement released early Tuesday.
"We urge the company to work with the DSMB to review the efficacy data and ensure the most...
AllSides Picks
May 11th, 2024
May 9th, 2024